Featured Research

from universities, journals, and other organizations

New antibiotic shows promise for treating MRSA pneumonia

Date:
September 11, 2013
Source:
Henry Ford Health System
Summary:
A drug approved just two years ago for treating bacterial infections may hold promise for treating the potentially fatal MRSA pneumonia, according to a new study. Researchers found that patients treated with the antibiotic ceftaroline fosamil, or CPT-F, had a lower mortality rate after 28 days than the mortality rate seen in patients treated with vancomycin, the most common drug therapy for MRSA pneumonia.

A drug approved just two years ago for treating bacterial infections may hold promise for treating the potentially fatal MRSA pneumonia, according to a Henry Ford Hospital study.

Researchers found that patients treated with the antibiotic ceftaroline fosamil, or CPT-F, had a lower mortality rate after 28 days than the mortality rate seen in patients treated with vancomycin, the most common drug therapy for MRSA pneumonia.

In the retrospective study, 33 of 38 patients responded well to treatments of CPT-F and were discharged from the hospital after the infection cleared. Of the five patients who died, three were attributed to other serious medical conditions.

The mortality rate for patients treated with vancomycin has been reported to be as high as 32 percent after 28 days. In the Henry Ford study, the mortality rate for the CPT-F treated population was 13 percent.

The study is being presented Wednesday at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy meeting in Denver.

"Many things fall under the umbrella of proper and appropriate MRSA pneumonia treatment, and these results present a possible benefit with the use of CPT-F," says Samia Arshad, a Henry Ford Infectious Diseases epidemiologist and the study's lead author. "It is critical for us to find alternative drug therapies to improve patient outcomes. Further research is needed to test the efficacy of CPT-F on a larger patient population as CPT-F offers doctors another viable option for treating patients with MRSA pneumonia."

In 2010 the U.S. Food and Drug Administration approved CPT-F, an injectable antibiotic, for treating patients with bacterial infections like community-acquired bacterial pneumonia and skin infections. Henry Ford's study is the first to evaluate the efficacy of MRSA pneumonia patients treated with CPT-F. MRSA pneumonia is highly antibiotic resistant and most common in patients 65 years or older.

Researchers evaluated 38 patients treated with CPT-F. Twenty of these patients were failing standard treatment with either vancomycin and/or cefepime, and were switched to CPT-F. Researchers say no complications were reported in those 20 patients.

Researchers will continue to look for other patients treated with CPT-F for MRSA pneumonia, and will match these patients to others treated with different antibiotics to conduct a matched cohort analysis.

The study was funded by Forest Laboratories, Inc.


Story Source:

The above story is based on materials provided by Henry Ford Health System. Note: Materials may be edited for content and length.


Cite This Page:

Henry Ford Health System. "New antibiotic shows promise for treating MRSA pneumonia." ScienceDaily. ScienceDaily, 11 September 2013. <www.sciencedaily.com/releases/2013/09/130911131734.htm>.
Henry Ford Health System. (2013, September 11). New antibiotic shows promise for treating MRSA pneumonia. ScienceDaily. Retrieved September 22, 2014 from www.sciencedaily.com/releases/2013/09/130911131734.htm
Henry Ford Health System. "New antibiotic shows promise for treating MRSA pneumonia." ScienceDaily. www.sciencedaily.com/releases/2013/09/130911131734.htm (accessed September 22, 2014).

Share This



More Health & Medicine News

Monday, September 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins